Brief: Nanoform - Additional Positive Interim Results From Nanoform's Clinical Study

Nanoform Finland Oyj

24/02/2021 06:23

Feb 24 (Reuters) - Nanoform Finland Plc  NANOFH.HE :
    * ADDITIONAL POSITIVE INTERIM RESULTS FROM NANOFORM'S CLINICAL STUDY
    * NANOFORM FINLAND PLC - SECOND INTERIM PHARMACOKINETIC (PK) STUDY RESULTS RELATED TO ITS
PHASE 1
STUDY DESIGNED TO EVALUATE PK PROFILE OF PIROXIC
    * NANOFORM FINLAND PLC - FASTER ABSORPTION OF NANOFORM'S CESS(®) NANOFORMED FORMULATION
AGAINST
FELDEN(®), REFERENCE PRODUCT, MARKETED BY PFIZER
    * NANOFORM FINLAND PLC - CESS(®) NANOPARTICLES MAY OFFER VIABLE ALTERNATIVES TO COMPLEX
FORMULATIONS
    * NANOFORM FINLAND PLC - IT IS POTENTIALLY POSSIBLE TO ACHIEVE INCREASED DRUG LOADS AND
SMALLER
DOSAGE FORMS
    * NANOFORM FINLAND PLC - SET OF HUMAN DATA SUPPORTS NANOFORM'S CLAIM THAT NANOPARTICLES CAN
ENABLE
FASTER DISSOLUTION RATE

Source text for Eikon:  ID:nWkr9zQplH 
Further company coverage:  NANOFH.HE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))